WO2018201930A1 - Dispositif automatique d'injection de médicament - Google Patents

Dispositif automatique d'injection de médicament Download PDF

Info

Publication number
WO2018201930A1
WO2018201930A1 PCT/CN2018/084235 CN2018084235W WO2018201930A1 WO 2018201930 A1 WO2018201930 A1 WO 2018201930A1 CN 2018084235 W CN2018084235 W CN 2018084235W WO 2018201930 A1 WO2018201930 A1 WO 2018201930A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood glucose
injection
unit
days
compared
Prior art date
Application number
PCT/CN2018/084235
Other languages
English (en)
Chinese (zh)
Inventor
张艳
梁曦
王舒
Original Assignee
张艳
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 张艳 filed Critical 张艳
Publication of WO2018201930A1 publication Critical patent/WO2018201930A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2006—Having specific accessories
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/18—General characteristics of the apparatus with alarm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/19—Constructional features of carpules, syringes or blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/201—Glucose concentration

Definitions

  • the present invention relates to an automatic drug injection device, and more particularly to an insulin injection device for a diabetic.
  • Diabetes is a common disease in our lives. It is well known that diabetes is a group of metabolic diseases characterized by hyperglycemia, which is caused by the fact that the pancreas cannot produce a sufficient amount of insulin, which leads to a decrease in the body's ability to metabolize glucose, and thus to hyperglycemia (ie, excessive glucose in the plasma). ). Long-term studies have found that persistent hyperglycemia and / or hypoinsulinemia are associated with a variety of serious symptoms and life-threatening complications such as dehydration, ketoacidosis, cardiovascular disease, chronic renal failure, retinal damage and each Neuropathy. With the improvement of living standards, the incidence of diabetes is also increasing. Especially in recent years, the prevalence of diabetes in China has shown a trend of rapid increase and rejuvenation.
  • Existing insulin injection devices generally use a conventional needle for insulin injection, and the needle has a significant pain when puncturing the skin.
  • the user wears the existing insulin injection device for a long time and needs the needle to stay in the skin for a long time, it is necessary to take disinfection measures from time to time, otherwise the wound infection and allergies may be caused by sweat and the like.
  • the needle since the needle needs to penetrate the dermis layer for insulin injection, the needle is generally long, and long-term wear is also likely to cause scarring of the skin.
  • the existing insulin injection device uses an ordinary needle for insulin injection, the injection position is concentrated, which tends to cause subcutaneous induration at the injection site, giving the patient an uncomfortable feeling. Further, due to the concentrated injection position, insulin absorption is likely to be slow, resulting in poor therapeutic effect.
  • the object of the present invention is to provide an automatic drug injection device, which can solve the problems of inconvenient use, painfulness to the patient, slow drug absorption, and poor therapeutic effect in the prior art drug injection device.
  • the present invention provides an automatic drug injection device comprising: an injection unit comprising at least two injection members, and each injection member is for injecting a drug; a calculation unit for calculating a drug The total injection volume; and the control unit, the control unit controls the injection unit according to the calculation result of the calculation unit; wherein the calculation unit is based on the patient's body weight, waist-to-hip ratio, blood triglyceride content, blood glucose monitoring value, and recent blood glucose change trend Calculate the total amount of drug injected.
  • the injection unit includes at least two injection parts, simultaneous injection of the medicine by the at least two injection parts can effectively increase the injection area of the medicine, significantly improve the skin induration, and effectively Enhance the absorption of the drug and enhance the therapeutic effect.
  • an automatic drug injection device wherein: the calculation unit is based on a patient's body weight, a waist-to-hip ratio, a blood triglyceride content, a single-day pre-prandial blood glucose monitoring mean value, and a three-day blood glucose change trend. Calculating the total amount of drug injected; and
  • the calculation unit calculates the total injection amount of the drug according to the following formula:
  • K body weight (Kg) of the subject to be injected
  • A mean daily pre-meal blood glucose (mmol/L) of the injected subject
  • the pre-meal blood glucose changes generally increased during the three days after injection, and the maximum value of blood glucose increased by more than 10% and within 20% compared with the minimum blood glucose level: a 1.2;
  • the pre-meal blood glucose changes generally increased during the three days after injection, and the maximum value of blood glucose increased by more than 20% and within 30% compared with the minimum blood glucose level: a 1.3;
  • the pre-meal blood glucose changes generally increased during the three days of the injection, and the maximum value of blood glucose increased by more than 40% compared with the minimum blood glucose level: a 1.5;
  • an automatic drug injection device wherein: the calculation unit is based on a patient's body weight, a waist-to-hip ratio, a blood triglyceride content, a single-day pre-prandial blood glucose monitoring mean, and a single-day meal.
  • the mean value of post-blood glucose monitoring, and the trend of blood glucose changes within three days to calculate the total injection volume of the drug;
  • the calculation unit calculates the total injection amount of the drug according to the following formula:
  • K body weight (Kg) of the subject to be injected
  • A mean daily pre-meal blood glucose (mmol/L) of the injected subject
  • the pre-meal blood glucose changes generally increased during the three days after injection, and the maximum value of blood glucose increased by more than 10% and within 20% compared with the minimum blood glucose level: a 1.2;
  • the pre-meal blood glucose changes generally increased during the three days after injection, and the maximum value of blood glucose increased by more than 20% and within 30% compared with the minimum blood glucose level: a 1.3;
  • the pre-meal blood glucose changes generally increased during the three days of the injection, and the maximum value of blood glucose increased by more than 40% compared with the minimum blood glucose level: a 1.5;
  • the calculation unit calculates the total injection amount of the drug according to the patient's body weight, waist-to-hip ratio, blood triglyceride content, blood glucose monitoring value, and recent blood glucose change tendency, thereby comparing
  • the existing insulin injection device can perform insulin injection with accurate values according to the patient's own characteristics, thereby avoiding the uncomfortable influence on the patient due to insufficient medication or excessive medication.
  • an automatic drug injection device wherein: the injection unit further comprises a drug storage member, a drug dispensing passage, and a syringe pump; and, the control unit performs a syringe pump according to a calculation result of the calculation unit Control is performed to deliver the drug in the drug storage component to the injection component through the drug delivery path in the desired amount.
  • the automatic drug injection device further comprising: a substrate formed of a flexible material; wherein each of the injection members in the injection unit is formed to be attached to the substrate at one end One side surface of the needle-shaped member having a fluid passage formed therein; and the other end of each injection member is formed as a tip end.
  • the automatic drug injection device further includes: an input unit, the user can input the personal information into the automatic drug injection device through the input unit, and the calculation unit inputs the personal information according to the user. Performing a calculation; and setting a unit that sets the automatic drug injection device; and the input unit and the setting unit are electrically connected to the control unit.
  • the automatic drug injection device further includes: a display unit configured to display a calculation result of the calculation unit; and a storage unit that stores the calculation result of the calculation unit;
  • the display unit and the storage unit are electrically connected to the control unit, respectively.
  • the automatic drug injection device further includes: a prompting unit, when the calculation result of the calculating unit is less than a preset threshold, the prompting unit issues a prompt to the user; and, the prompting unit and The control unit is electrically connected.
  • the automatic drug injection device further includes: a transmitting unit configured to transmit a calculation result of the computing unit and/or a calculation result stored in the storage unit.
  • an automatic drug injection device wherein: the calculation unit, the display unit, the storage unit, the input unit, the setting unit, the transmitting unit, and the control unit are packaged in the same housing.
  • Figure 1 is a schematic view showing the frame of an automatic drug injection device according to the present invention.
  • Figure 2a is a side elevational view showing the injection unit 1 and the substrate 12 of the automatic drug injection device according to the present invention
  • Fig. 2b is a perspective view showing the structure of the injection unit 1 and the substrate 12 of the automatic drug injection device according to the present invention.
  • the present invention provides an automatic drug injection device comprising: an injection unit 1 comprising at least two injection members 11, and each injection member 11 is used for injection Drug; calculation unit 2 for calculating the total injection amount of the medicine; and control unit 3, which controls the injection unit 1 according to the calculation result of the calculation unit 2.
  • the calculation unit 2 calculates the total injection amount of the drug based on the patient's body weight, waist-to-hip ratio, blood triglyceride content, blood glucose monitoring value, and recent blood glucose change tendency.
  • the injection member 11 may be an implantable syringe, or other internal syringes may be used for insertion of veins or other parts of the body containing body fluids.
  • the injection unit 1 includes at least two injection members 11, the drug injection can be simultaneously performed by the at least two injection members 11, which can effectively increase the injection area of the drug. Improves skin induration and effectively enhances drug absorption and enhances therapeutic effects.
  • an automatic drug injection device according to a preferred embodiment of the present invention, wherein: the calculation unit 2 is based on the patient's body weight, waist-to-hip ratio, blood triglyceride content, single-day pre-prandial blood glucose monitoring average, and within three days.
  • the blood glucose change trend calculates the total injection volume of the drug.
  • the calculation unit 2 calculates the total injection amount of the medicine according to the following formula:
  • K body weight (Kg) of the subject to be injected
  • A mean daily pre-meal blood glucose (mmol/L) of the injected subject
  • the pre-meal blood glucose changes generally increased during the three days after injection, and the maximum value of blood glucose increased by more than 10% and within 20% compared with the minimum blood glucose level: a 1.2;
  • the pre-meal blood glucose changes generally increased during the three days after injection, and the maximum value of blood glucose increased by more than 20% and within 30% compared with the minimum blood glucose level: a 1.3;
  • the pre-meal blood glucose changes generally increased during the three days of the injection, and the maximum value of blood glucose increased by more than 40% compared with the minimum blood glucose level: a 1.5;
  • the automatic drug injection device is calculated according to the patient's body weight, waist-to-hip ratio, blood triglyceride content, single-day pre-prandial blood glucose monitoring mean value, and pre-prandial blood glucose change trend within three days.
  • Unit 2 calculates the total amount of one-day pre-meal injection of insulin and injects it by the injection unit 1 prior to the meal to provide targeted, personalized treatment for each patient.
  • the calculation unit 2 calculates the mean value according to the patient's body weight, waist-to-hip ratio, blood triglyceride content, and single-day pre-prandial blood glucose monitoring. The average daily blood glucose monitoring, and the trend of blood glucose changes within three days to calculate the total injection volume of the drug;
  • the calculation unit calculates the total injection amount of the drug according to the following formula:
  • K body weight (Kg) of the subject to be injected
  • A mean daily pre-meal blood glucose (mmol/L) of the injected subject
  • the pre-meal blood glucose changes generally increased during the three days after injection, and the maximum value of blood glucose increased by more than 10% and within 20% compared with the minimum blood glucose level: a 1.2;
  • the pre-meal blood glucose changes generally increased during the three days after injection, and the maximum value of blood glucose increased by more than 20% and within 30% compared with the minimum blood glucose level: a 1.3;
  • the pre-meal blood glucose changes generally increased during the three days of the injection, and the maximum value of blood glucose increased by more than 40% compared with the minimum blood glucose level: a 1.5;
  • the automatic drug injection device is based on the patient's body weight, waist-to-hip ratio, blood triglyceride content, single-day pre-prandial blood glucose monitoring mean, single-day postprandial blood glucose monitoring mean, and three The intraday blood glucose change trend, the calculation unit 2 accurately calculates the total daily injection amount L 2 of each patient's insulin, and thereby obtains the patient's pre-breakfast drug injection amount L 21 and the pre-dinner drug injection amount L 22 , and Further precise injections are made by the injection unit 1 before breakfast and before dinner, so that targeted, personalized treatment is provided for each patient.
  • the injection unit 1 can perform accurate quantitative drug injection before breakfast and/or before dinner according to the calculation result of the calculation unit 2 for each patient's own specific situation.
  • the injection unit 1 includes at least two injection members 11, the simultaneous injection of the drug by the at least two injection members 11 can effectively increase the injection area of the drug, significantly improve the skin induration, and effectively enhance the drug absorption effect. Improve the treatment effect.
  • the injection unit 1 includes a plurality of injection members 11 arranged in an array, so that the drug injection area can be most effectively increased, the skin induration is improved, and the drug absorption effect is enhanced.
  • the automatic drug injection device wherein the injection unit 1 further includes a drug storage member (not shown), a drug dispensing passage 13, and a syringe pump (not shown); and, the control unit 3 Based on the calculation result of the calculation unit 2, the syringe pump is controlled to deliver the medicine in the drug storage member to the respective injection members through the drug distribution path in the required amount.
  • the structure of the drug storage component, the drug distribution channel 13 and the syringe pump is not illustrated in the drawings of the present invention, it can be arbitrarily selected by those skilled in the art according to actual design and use requirements.
  • the specific configuration of the drug storage member, the drug dispensing passage 13 and the syringe pump is provided, which does not require any additional inventive work.
  • the automatic drug injection device further includes: a substrate 12 formed of a flexible material.
  • each of the injection members 11 in the injection unit 1 is formed as a needle having a fluid passage formed therein with one end attached to one side surface of the substrate 12 (i.e., a side surface facing the human body surface in use) And the other end of each injection member 11 is formed as a tip end, and when the injection member 11 is inserted into the patient's skin, the drug flows from the drug storage member into the fluid passage inside each injection member 11 through the drug distribution passage 13 and passes through each The tip end of the injection member 11 flows into the patient.
  • the substrate 12 is flexible to reduce pain and tissue damage caused by implantation and/or wearing of the injection unit 1.
  • the flexible substrate 12 generally increases patient comfort and allows the patient to have a greater range of motion.
  • Suitable materials for the flexible substrate 12 include materials such as non-conductive plastics or polymers and other non-conductive, flexible, deformable materials.
  • useful plastic or polymeric materials include thermoplastics such as polycarbonate, polyethylene terephthalate (PET), polyvinyl chloride (PVC), polyurethane, polyether, polyamide, polyimide. , or a copolymer of these thermoplastics, such as PETG (ethylene glycol modified polyethylene terephthalate).
  • the substrate 12 in the automatic drug injection device according to the present invention may also be rigid depending on actual use and design requirements.
  • the rigid substrate 12 can be used to provide structural support to the injection unit 1 to resist bending or cracking.
  • examples of the rigid material that can be used as the substrate 12 include ceramics having poor conductivity such as alumina and silica. Another advantage of using a rigid substrate 12 is that it helps to detect that the injection member 11 is inserted without the need for additional insertion of the device.
  • the user inserts the injection member 11 provided on the substrate 12 into a predetermined position on the surface of the human body such that each injection member 11 is located in a vein or contains body fluid.
  • implantation of the injection member 11 can be performed in a venous system for directly injecting a drug into the blood.
  • the injection component 11 can be implanted into the interstitial tissue for injection of the drug into the interstitial fluid.
  • the position and depth of implantation of the injection member 11 can affect the specific shape, components, and structure of the injection member 11.
  • the injection member 11 disposed on the substrate 12 is inserted into the interstitial tissue of the patient (between 0.3 mm and 5 mm). Preferably, it is inserted into the interstitial tissue, 0.5 mm to 3 mm, more preferably 0.5 mm to 1.5 mm.
  • Other embodiments of the invention may include an injection unit 1 that is inserted into other parts of the patient, such as a vein or an organ. The depth of implantation varies depending on the target to be implanted.
  • a viscous substance may be applied on the surface of the substrate 12 on which the injection member 11 is provided, so that the injection member 11 is fixed to the patient through the viscous substance on the surface of the substrate 12 after the injection member 11 is inserted into the epidermis of the patient.
  • the body is thereby convenient for the patient to re-insert the injection member 11 each time for a period of time.
  • the insertion angle is measured from the skin surface (i.e., the insertion angle should be 90° perpendicular to the skin insertion sensor).
  • the insertion angle is typically in the range of 10° to 90°, typically 15° to 60°, and more often 30° to 45°.
  • each injection member 11 is substantially smaller in size than a conventional syringe needle, thereby performing drug injection using the injection member 11 provided by the present invention.
  • the pain of the patient is greatly reduced, and since the skin penetration depth of the injection member 11 is small, the wound infection is not caused, and the scar is not left due to the long-term wearing of the injection unit 1.
  • the patient can greatly reduce the pain of the patient when using the automatic drug injection device provided by the present invention.
  • the substrate 12 and the injection member 11 in the automatic drug injection device according to the present invention are formed into a shape that is comfortable for the patient, which may be allowed to be hidden under the clothes of, for example, a patient.
  • the thigh, leg, upper arm, shoulder or abdomen are the more convenient locations on the patient's body for placing the injection component 11 to remain hidden.
  • the injection member 11 can also be placed in other parts of the patient's body. It should be noted that the specific structure of the injection component 11 is only illustrated in the drawings of the present invention.
  • the structure of the injection component 11 can be arbitrarily selected according to actual design and use requirements.
  • the injection member 11 can be a planar osmotic injection structure, or any other structure capable of achieving the purpose of injection, without any additional inventive work.
  • the injection member 11 according to the present invention may be made of dimethyl siloxane (PDMS) or the like, and the surface may be coated with various anti-corrosion layers to function as a seal.
  • PDMS dimethyl siloxane
  • rigid and flexible substrates can be suitably used for many injection components 11 depending on the particular use and design requirements, as well as by, for example, changing the composition of the substrate 12 and / or thickness to continuously change its flexibility. These can all be determined by one skilled in the art based on the particular use and design needs.
  • the automatic drug injection device further includes: an input unit 4 through which the user can input personal information into the automatic drug injection device. More specifically, the user can input personal information such as his own weight, blood triglyceride content, blood glucose monitoring value and the like into the automatic drug injection device through the input unit 4, and then the calculation unit 2 according to the personal information input by the user, according to the present The method for calculating the total amount of insulin injection provided by the invention is calculated to obtain the total amount of insulin injection corresponding to the personal information, and further, the injection unit 1 performs the injection. Further, the automatic drug injection device according to the present invention further includes a setting unit 5 by which the user can set the automatic drug injection device provided by the present invention.
  • a setting unit 5 by which the user can set the automatic drug injection device provided by the present invention.
  • the user can set the automatic drug injection device provided by the present invention through the setting unit 5, for example, the use condition of the automatic drug injection device by the setting unit 5 (for example, the meal time of the patient)
  • the setting of the automatic injection device of the drug, etc. is set, so that the user can use the automatic injection device of the drug according to his actual needs.
  • the setting unit 5 is electrically connected to the control unit 3, so that various settings of the automatic drug injection device made by the user through the setting unit 5 can pass through the control unit 3. Control each other unit.
  • the input unit 4 and the setting unit 5 are electrically connected to the control unit 3, respectively, so that the input unit 4 and the setting unit 5 are controlled by the control unit 3, while the input unit 4 is simultaneously Various feedbacks with the setting unit 5 can also be fed back to the other individual units through the control unit 4.
  • the automatic drug injection device further includes: a display unit 6 for displaying a calculation result of the calculation unit 2. More specifically, as described above, according to the automatic drug injection device provided by the preferred embodiment of the present invention, the calculation unit 2 performs calculation based on the personal information of the patient to obtain an insulin injection amount for the individual patient. Further, the calculation result of the calculation unit 2 is displayed by the display unit 6, so that the patient can visually and immediately see the calculation result of the calculation unit 2 through the display unit 6, thereby knowing the total amount of drugs to be injected into the body, and understanding the disease treatment. status.
  • the display unit 6 can also display personal information such as body weight, blood triglyceride content, blood glucose monitoring value input by the patient through the input unit 4, thereby understanding his or her physical condition.
  • the automatic drug injection device further includes a storage unit 7, which stores the calculation result of the calculation unit 2. More specifically, the storage unit 7 can be arranged to store a plurality of calculation results of the computing unit 2 for a period of time (for example, 72 hours or longer), thereby facilitating the user from the storage unit 7 to the time. The calculation results in the cycle are extracted and analyzed, and the use of the drug in the time period, as well as the state change of the body, and various adjustments are further obtained.
  • the display unit 6 and the storage unit 7 are electrically connected to the control unit 3, respectively, so that the display unit 6 and the storage unit 7 are controlled by the control unit 3, while the display unit 6 and the storage unit are simultaneously stored.
  • the various feedbacks of unit 7 can also be fed back to the other individual units via control unit 3.
  • the automatic drug injection device further includes a prompting unit 8 that issues a prompt to the user when the calculation result of the calculating unit 2 is less than a preset threshold. More specifically, in the automatic drug injection device according to the preferred embodiment of the present invention, the prompting unit 8 compares the insulin injection amount calculated by the calculation unit 2 (i.e., L 1 or L 2 as described above) with The set threshold is compared, and when the calculation result of the calculation unit 2 (ie, the insulin injection amount) is less than a preset threshold, the prompting unit 8 issues a prompt to the user.
  • the calculation unit 2 i.e., L 1 or L 2 as described above
  • a preset threshold may be stored in the control unit 3 or the prompting unit 8, and the threshold may be 5u (corresponding to the L 1 calculated by the computing unit 2) ) or 10U (corresponding to the calculated calculation unit 2 L 2), if calculated by the calculating unit 2 is smaller than L 1 of 5U (or computing unit 2 is smaller than the calculated 10U L 2), then sent to the user prompting unit 8
  • the prompt prompts the user to choose not to inject insulin in this case, and to control the blood sugar in the body by oral medication or, for example, controlling diet.
  • the cueing unit 8 may include a component that prompts the user by a lamp or sound, such as a sounding component or a lighting component.
  • the prompting unit 8 is electrically connected to the control unit 3, so that the prompting unit 8 is controlled by the control unit 3, and various feedbacks of the prompting unit 8 can also be fed back through the control unit 3. Go to each other unit.
  • the control unit 3 controls the injection unit 1 not to inject the patient according to the feedback of the prompting unit 8, thereby facilitating the patient to control the blood sugar in the body by oral medication or, for example, controlling diet. .
  • an analyte monitoring apparatus further includes: a transmitting unit 9 for transmitting a calculation result of the calculation unit 2 and/or a calculation result stored in the storage unit 7. More specifically, according to a preferred embodiment of the present invention, the transmitting unit 9 can transmit the calculation result of the computing unit 2 and the manner of wired (for example, a data transmission line) or wireless (for example, a wireless network, Bluetooth transmission, etc.). / or the calculation result stored in the storage unit 7. Thereby the user can obtain the calculation result of the calculation unit 2 and/or the calculation result stored in the storage unit 7 by, for example, a wired/wireless handheld device.
  • wired for example, a data transmission line
  • wireless for example, a wireless network, Bluetooth transmission, etc.
  • the application software (mobile phone App) adapted to the automatic drug injection device provided by the present invention is installed in the user's mobile phone, it can be paired with the transmitting unit 9 (for example, Bluetooth pairing, wireless network pairing, etc.) Therefore, the calculation result of the calculation unit 2 and/or the calculation result stored in the storage unit 7 can be easily obtained on the mobile phone, and the physical state of the patient can be grasped at any time.
  • the transmitting unit 9 for example, Bluetooth pairing, wireless network pairing, etc.
  • the automatic drug injection device the calculation unit 2, the input unit 4, the setting unit 5, the display unit 6, the storage unit 7, the prompting unit 8, the transmitting unit 9, and the control unit 3 are packaged in the same In the housing.
  • the drug storage member (not shown) included in the injection unit 1 and a syringe pump (not shown) are also included in the same casing and through the drug distribution path. It is in fluid communication with the injection component 11.
  • the housing is at least waterproof to prevent inflow of liquid into contact with components in the housing.
  • the housing is formed as a sealed, waterproof or water resistant seal so that liquid cannot flow into the interior of the housing, which is very useful when the user is performing activities such as showering, bathing or swimming.
  • the shape of the housing may be arbitrarily selected according to actual design and use requirements.
  • the housing may be formed in a circular, elliptical or other various shape as long as it is adapted to the user's body.
  • the preferred embodiment of the present invention only describes a drug (insulin) injection method for treating a disease (diabetes).
  • the automatic drug injection device provided by the present invention can be used for drug injection of various diseases, for example, for controlling injection of drugs such as hyperlipemia and hypertension. This can be arbitrarily chosen according to the actual use, which does not require any additional creative labor.

Abstract

L'invention concerne un dispositif automatique d'injection de médicament, comprenant : une unité d'injection (1) constituée d'au moins deux composants d'injection (11), chaque composant d'injection (11) servant à injecter un médicament ; une unité de calcul (2) servant à calculer une quantité d'injection totale du médicament ; et une unité de commande (3), l'unité de commande (3) assurant la commande de l'unité d'injection (1) en fonction d'un résultat de calcul provenant de l'unité de calcul (2). L'unité d'injection (1) comprend au moins deux composants d'injection (11), permettant ainsi des injections de médicament simultanées par l'intermédiaire desdits deux composants d'injection (11) au moins, ce qui permet d'élargir efficacement la zone d'injections de médicament, réduisant ainsi de façon significative les noeuds cutanés durs et améliorant efficacement l'absorption de médicament ainsi que les effets thérapeutiques.
PCT/CN2018/084235 2017-05-04 2018-04-24 Dispositif automatique d'injection de médicament WO2018201930A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710307841.0A CN107050578A (zh) 2017-05-04 2017-05-04 一种药物自动注射装置
CN201710307841.0 2017-05-04

Publications (1)

Publication Number Publication Date
WO2018201930A1 true WO2018201930A1 (fr) 2018-11-08

Family

ID=59596049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/084235 WO2018201930A1 (fr) 2017-05-04 2018-04-24 Dispositif automatique d'injection de médicament

Country Status (2)

Country Link
CN (1) CN107050578A (fr)
WO (1) WO2018201930A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107050578A (zh) * 2017-05-04 2017-08-18 梁曦 一种药物自动注射装置

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080097553A1 (en) * 2005-08-31 2008-04-24 John Michael S Methods and Systems for semi-automatic adjustment of medical monitoring and treatment
CN102406972A (zh) * 2011-09-26 2012-04-11 肖俊涛 医用定量输注装置
CN102905753A (zh) * 2009-12-24 2013-01-30 因卡伯实验室有限责任公司 可吞咽式药剂递送装置和药剂递送方法
CN203060453U (zh) * 2013-02-01 2013-07-17 杭州电子科技大学 一种集成微泵与微针阵列的闭环胰岛素输送装置
WO2016019192A1 (fr) * 2014-08-01 2016-02-04 Becton, Dickinson And Company Dispositif d'injection pour surveillance continue du glucose
CN106983951A (zh) * 2017-05-04 2017-07-28 梁曦 一种分析物监测与自动给药系统
CN107050578A (zh) * 2017-05-04 2017-08-18 梁曦 一种药物自动注射装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8615366B2 (en) * 2010-10-15 2013-12-24 Roche Diagnostics Operations, Inc. Handheld diabetes management device with bolus calculator
US9136939B2 (en) * 2011-12-29 2015-09-15 Roche Diabetes Care, Inc. Graphical user interface pertaining to a bolus calculator residing on a handheld diabetes management device
US20140121634A1 (en) * 2012-07-11 2014-05-01 Caren Frances Thomson Method, system and apparatus for setting insulin dosages for diabetics
EP2873014A4 (fr) * 2012-07-11 2016-04-27 Caren Frances Thomson Procédé, système et appareil pour déterminer des dosages d'insuline pour les diabétiques
CN103495231A (zh) * 2013-10-16 2014-01-08 李秀 智能药物释放装置
CN205181355U (zh) * 2015-10-12 2016-04-27 济南百博生物技术股份有限公司 一种可自动计算胰岛素注射量的血糖测试预警系统
CN205626630U (zh) * 2016-03-11 2016-10-12 成都市亿泰科技有限公司 基于云计算的智能胰岛素便携式注射装置

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080097553A1 (en) * 2005-08-31 2008-04-24 John Michael S Methods and Systems for semi-automatic adjustment of medical monitoring and treatment
CN102905753A (zh) * 2009-12-24 2013-01-30 因卡伯实验室有限责任公司 可吞咽式药剂递送装置和药剂递送方法
CN102406972A (zh) * 2011-09-26 2012-04-11 肖俊涛 医用定量输注装置
CN203060453U (zh) * 2013-02-01 2013-07-17 杭州电子科技大学 一种集成微泵与微针阵列的闭环胰岛素输送装置
WO2016019192A1 (fr) * 2014-08-01 2016-02-04 Becton, Dickinson And Company Dispositif d'injection pour surveillance continue du glucose
CN106983951A (zh) * 2017-05-04 2017-07-28 梁曦 一种分析物监测与自动给药系统
CN107050578A (zh) * 2017-05-04 2017-08-18 梁曦 一种药物自动注射装置

Also Published As

Publication number Publication date
CN107050578A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
WO2018201931A1 (fr) Système de surveillance d'analyte et d'administration automatique de médicament
US20230125668A1 (en) Systems for determining insulin on board and recommending insulin therapy, and related methods
US10279105B2 (en) System and method for modifying medicament delivery parameters after a site change
KR20220132615A (ko) 리던던트 스태거링된 포도당 센서 질병 관리 시스템
US20100268043A1 (en) Device and Method for Preventing Diabetic Complications
CN101489603A (zh) 在佩戴时间期间具有医疗输注补偿的灌注装置
WO2010113159A1 (fr) Dispositifs et procédés pour augmenter la vitesse d'absorption d'un médicament
WO2006083831A1 (fr) Estimateur de bolus pour systeme de perfusion en boucle semi-fermee
CN106860956A (zh) 一种柔性微泵驱动的慢性病便携式自动监测/给药装置
US20160022905A1 (en) Device, system and method for subcutaneous drug delivery
WO2018201930A1 (fr) Dispositif automatique d'injection de médicament
Kang et al. Contributions of basal glucose and postprandial glucose concentrations to hemoglobin A1c in the newly diagnosed patients with type 2 diabetes—the preliminary study
Takahashi et al. A survey of insulin-dependent diabetes—part I: therapies and devices
US11617832B2 (en) Portal system-based bionic pancreas
CN209033359U (zh) 一种药物自动注射系统
CN110876823A (zh) 一种药物自动注射系统
KR20170056904A (ko) 연속 혈당 감지를 이용한 인슐린 투여 시스템
Guimarães et al. Impacto das novas tecnologias no tratamento do Diabetes Mellitus: Impact of new technologies in the treatment of Diabetes Mellitus
CN110876624A (zh) 一种分析物监测与自动给药系统
Brown 21st-century diabetes: Technology leads the way
Selvan et al. Insulin pump–A review
Kozlova The features of insulin pump therapy for treatment of diabetes mellitus
Taylor et al. New technologies in insulin delivery
Brindha et al. Implementation of Multi-Functional Pump Therapy
Kruger Integrating innovative tools into the management of type 2 diabetes to improve patient self-management

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18793778

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18793778

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07-04-2020

122 Ep: pct application non-entry in european phase

Ref document number: 18793778

Country of ref document: EP

Kind code of ref document: A1